The Relationships Between Mycophenolic Acid Levels, T-Cell Subsets and Outcomes in Pediatric Heat Transplant Recipients Receiving Mycophenolate Mofetil (Cellcept) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2003-2005

ABSTRACT

The survival of children who have received heart transplants has greatly improved over the last ten years. One reason for this is better control over rejection. Rejection medications require a delicate balance of enough medicine to work without causing side effects. It is a goal to avoid both rejection and side effects from the anti-rejection medicines. Usually several medicines are used together to prevent rejection. One of these medicines is often Mycophenolic Acid or CellceptThis medicine has been used longer for adults than is has for children. More information is needed on using it for children. The dose is usually determined by the patient's weight or body surface area. There have been some early studies of the use of Cellcept, but none have proven a relationship between the blood level of the drug and how well it works. More also needs to be known about how this drug works with other anti-rejection drugs and how it works in boys and girls. This study will look more closely at proper dosing, how Cellcept works with other anti-rejection medications, side effects, and any differences in how this medicine works in boys and girls. All patients in the study will be receiving Cellcept and have blood levels of the drug drawn. Results of their usual treatment and testing will be recorded and evaluated for signs of rejection. All the information will be analyzed. Results of this study will be reported to transplant committees locally and nationally. Detailed Description Pediatric heart transplant recipients receiving MMF will undergo study testing to measure MPA levels by the HPLC method and T-cell subsets by flow cytometry method. As standard of care they receive histological grading of routine endomyocardial biopsies using the International Society of Heart Lung Transplantation (ISHLT) grading scale. The data obtained from standard assessments will include medications, echocardiographic reports, pre-and post biopsy assessments/physical exams, hospital records for any inpatient hospitalization, and any laboratory assessments. Also, information will be collected on all patients which will be examined for tolerance and success (side effects and rejection) of immunosuppressive therapy. In newly transplanted patients, study testing will occur at the same time as standard of care biopsies which are typically 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months. If the patient has additional visits due to rejection or changes in immunosuppression, then more frequent study testing may be done per investigator preference. Previously transplanted patients will have study testing at the same time as their standard of care visits, usually annually. More... »

URL

https://clinicaltrials.gov/show/NCT00166153

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3164", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The survival of children who have received heart transplants has greatly improved over the last ten years. One reason for this is better control over rejection. Rejection medications require a delicate balance of enough medicine to work without causing side effects. It is a goal to avoid both rejection and side effects from the anti-rejection medicines. Usually several medicines are used together to prevent rejection. One of these medicines is often Mycophenolic Acid or CellceptThis medicine has been used longer for adults than is has for children. More information is needed on using it for children. The dose is usually determined by the patient's weight or body surface area. There have been some early studies of the use of Cellcept, but none have proven a relationship between the blood level of the drug and how well it works. More also needs to be known about how this drug works with other anti-rejection drugs and how it works in boys and girls. This study will look more closely at proper dosing, how Cellcept works with other anti-rejection medications, side effects, and any differences in how this medicine works in boys and girls. All patients in the study will be receiving Cellcept and have blood levels of the drug drawn. Results of their usual treatment and testing will be recorded and evaluated for signs of rejection. All the information will be analyzed. Results of this study will be reported to transplant committees locally and nationally.\n\nDetailed Description\nPediatric heart transplant recipients receiving MMF will undergo study testing to measure MPA levels by the HPLC method and T-cell subsets by flow cytometry method. As standard of care they receive histological grading of routine endomyocardial biopsies using the International Society of Heart Lung Transplantation (ISHLT) grading scale. The data obtained from standard assessments will include medications, echocardiographic reports, pre-and post biopsy assessments/physical exams, hospital records for any inpatient hospitalization, and any laboratory assessments. Also, information will be collected on all patients which will be examined for tolerance and success (side effects and rejection) of immunosuppressive therapy. In newly transplanted patients, study testing will occur at the same time as standard of care biopsies which are typically 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months. If the patient has additional visits due to rejection or changes in immunosuppression, then more frequent study testing may be done per investigator preference. Previously transplanted patients will have study testing at the same time as their standard of care visits, usually annually.", 
    "endDate": "2005-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00166153", 
    "keywords": [
      "mycophenolic acid", 
      "T cell subset", 
      "mycophenolate mofetil", 
      "survival", 
      "child", 
      "heart transplant", 
      "good control", 
      "rejection", 
      "medication", 
      "delicate balance", 
      "medicine", 
      "side effect", 
      "adult", 
      "dose", 
      "patient", 
      "weight", 
      "body surface area", 
      "early study", 
      "blood level", 
      "drug", 
      "boy", 
      "girl", 
      "dosing", 
      "difference", 
      "usual treatment", 
      "sign", 
      "Transplant", 
      "heart transplant recipient", 
      "MMF", 
      "study testing", 
      "MPa", 
      "HPLC method", 
      "T-Lymphocyte Subset", 
      "flow cytometry", 
      "care", 
      "grading", 
      "endomyocardial biopsy", 
      "International Society", 
      "standard assessment", 
      "biopsy", 
      "hospital record", 
      "inpatient hospitalization", 
      "laboratory assessment", 
      "tolerance", 
      "success", 
      "immunosuppressive therapy", 
      "transplanted patient", 
      "same time", 
      "visit", 
      "Immune Tolerance", 
      "preference"
    ], 
    "name": "The Relationships Between Mycophenolic Acid Levels, T-Cell Subsets and Outcomes in Pediatric Heat Transplant Recipients Receiving Mycophenolate Mofetil (Cellcept)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00166153"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00001.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.428158.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.189967.8", 
        "type": "Organization"
      }
    ], 
    "startDate": "2003-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/s1053-2498(01)00305-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022780452"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00007691-200110000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041750685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1011406022657", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046923234", 
          "https://doi.org/10.1023/a:1011406022657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074714504", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082581771", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00166153"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00166153'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00166153'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00166153'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00166153'


 

This table displays all metadata directly associated to this object as RDF triples.

86 TRIPLES      16 PREDICATES      72 URIs      60 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00166153 schema:about anzsrc-for:3164
2 schema:description The survival of children who have received heart transplants has greatly improved over the last ten years. One reason for this is better control over rejection. Rejection medications require a delicate balance of enough medicine to work without causing side effects. It is a goal to avoid both rejection and side effects from the anti-rejection medicines. Usually several medicines are used together to prevent rejection. One of these medicines is often Mycophenolic Acid or CellceptThis medicine has been used longer for adults than is has for children. More information is needed on using it for children. The dose is usually determined by the patient's weight or body surface area. There have been some early studies of the use of Cellcept, but none have proven a relationship between the blood level of the drug and how well it works. More also needs to be known about how this drug works with other anti-rejection drugs and how it works in boys and girls. This study will look more closely at proper dosing, how Cellcept works with other anti-rejection medications, side effects, and any differences in how this medicine works in boys and girls. All patients in the study will be receiving Cellcept and have blood levels of the drug drawn. Results of their usual treatment and testing will be recorded and evaluated for signs of rejection. All the information will be analyzed. Results of this study will be reported to transplant committees locally and nationally. Detailed Description Pediatric heart transplant recipients receiving MMF will undergo study testing to measure MPA levels by the HPLC method and T-cell subsets by flow cytometry method. As standard of care they receive histological grading of routine endomyocardial biopsies using the International Society of Heart Lung Transplantation (ISHLT) grading scale. The data obtained from standard assessments will include medications, echocardiographic reports, pre-and post biopsy assessments/physical exams, hospital records for any inpatient hospitalization, and any laboratory assessments. Also, information will be collected on all patients which will be examined for tolerance and success (side effects and rejection) of immunosuppressive therapy. In newly transplanted patients, study testing will occur at the same time as standard of care biopsies which are typically 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months. If the patient has additional visits due to rejection or changes in immunosuppression, then more frequent study testing may be done per investigator preference. Previously transplanted patients will have study testing at the same time as their standard of care visits, usually annually.
3 schema:endDate 2005-05-01T00:00:00Z
4 schema:keywords HPLC method
5 Immune Tolerance
6 International Society
7 MMF
8 MPa
9 T cell subset
10 T-Lymphocyte Subset
11 Transplant
12 adult
13 biopsy
14 blood level
15 body surface area
16 boy
17 care
18 child
19 delicate balance
20 difference
21 dose
22 dosing
23 drug
24 early study
25 endomyocardial biopsy
26 flow cytometry
27 girl
28 good control
29 grading
30 heart transplant
31 heart transplant recipient
32 hospital record
33 immunosuppressive therapy
34 inpatient hospitalization
35 laboratory assessment
36 medication
37 medicine
38 mycophenolate mofetil
39 mycophenolic acid
40 patient
41 preference
42 rejection
43 same time
44 side effect
45 sign
46 standard assessment
47 study testing
48 success
49 survival
50 tolerance
51 transplanted patient
52 usual treatment
53 visit
54 weight
55 schema:name The Relationships Between Mycophenolic Acid Levels, T-Cell Subsets and Outcomes in Pediatric Heat Transplant Recipients Receiving Mycophenolate Mofetil (Cellcept)
56 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00166153
57 schema:sdDatePublished 2019-03-07T15:21
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N286953d584f24cbba7b1b95496c393f6
60 schema:sponsor https://www.grid.ac/institutes/grid.189967.8
61 https://www.grid.ac/institutes/grid.428158.2
62 schema:startDate 2003-01-01T00:00:00Z
63 schema:subjectOf sg:pub.10.1023/a:1011406022657
64 https://app.dimensions.ai/details/publication/pub.1074714504
65 https://app.dimensions.ai/details/publication/pub.1082581771
66 https://doi.org/10.1016/s1053-2498(01)00305-9
67 https://doi.org/10.1097/00007691-200110000-00004
68 schema:url https://clinicaltrials.gov/show/NCT00166153
69 sgo:license sg:explorer/license/
70 sgo:sdDataset clinical_trials
71 rdf:type schema:MedicalStudy
72 N286953d584f24cbba7b1b95496c393f6 schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 anzsrc-for:3164 schema:inDefinedTermSet anzsrc-for:
75 rdf:type schema:DefinedTerm
76 sg:pub.10.1023/a:1011406022657 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046923234
77 https://doi.org/10.1023/a:1011406022657
78 rdf:type schema:CreativeWork
79 https://app.dimensions.ai/details/publication/pub.1074714504 schema:CreativeWork
80 https://app.dimensions.ai/details/publication/pub.1082581771 schema:CreativeWork
81 https://doi.org/10.1016/s1053-2498(01)00305-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022780452
82 rdf:type schema:CreativeWork
83 https://doi.org/10.1097/00007691-200110000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041750685
84 rdf:type schema:CreativeWork
85 https://www.grid.ac/institutes/grid.189967.8 schema:Organization
86 https://www.grid.ac/institutes/grid.428158.2 schema:Organization
 




Preview window. Press ESC to close (or click here)


...